Recommendations derived from our data depend on the specific setting and the purpose of [18F]PI-2620 tau-PET imaging in PSP, which can be roughly divided in (I) therapy monitoring of tau-targeting therapies, (II) PET imaging as an inclusion criteria of clinical trial, (III) observational studies, and (IV) clinical differential diagnosis. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.